Proton magnetic resonance spectroscopic imaging (1H MRSI) enables non-invasive assessment of certain metabolites in the prostate gland. Several studies have demonstrated that this metabolic ...information, in combination with anatomical information from T2-weighted MR imaging significantly improves prostate cancer detection, localization and disease characterization. The technology of 1H MRSI is continuously evolving with improvements of hardware and acquisition methods. Recently, 31P and 13C MRSI of the prostate have regained new interest after a dormant period of decades.
This review focuses on recent technical progress of in vivo1H MRSI of the prostate, in particular those that enhance clinical applicability at 3T with respect to commonly used techniques to examine the prostate. These developments consist of higher magnetic field strengths, and better MR coils and acquisition techniques. Besides the improvements for 1H MRSI, the developments and opportunities for 31P and 13C MRSI for the prostate are reviewed. Finally, we briefly review 13C MRS of the prostate, in particular the new possibilities with hyperpolarized substrates.
Purpose:
To investigate the associations of metabolite levels derived from magnetic resonance spectroscopic imaging (MRSI) and
18
F-fluciclovine positron emission tomography (PET) with prostate ...tissue characteristics.
Methods:
In a cohort of 19 high-risk prostate cancer patients that underwent simultaneous PET/MRI, we evaluated the diagnostic performance of MRSI and PET for discrimination of aggressive cancer lesions from healthy tissue and benign lesions. Data analysis comprised calculations of correlations of mean standardized uptake values (SUV
mean
), maximum SUV (SUV
max
), and the MRSI-derived ratio of (total choline + spermine + creatine) to citrate (CSC/C). Whole-mount histopathology was used as gold standard.
Results:
The results showed a moderate significant correlation between both SUVmean and SUVmax with CSC/C ratio.
Conclusions:
We demonstrated that the simultaneous acquisition of
18
F-fluciclovine PET and MRSI with an integrated PET/MRI system is feasible and a combination of these imaging modalities has potential to improve the diagnostic sensitivity and specificity of prostate cancer lesions.
Purpose
Until now, 1H MRSI of the prostate has been performed with suppression of the large water signal to avoid distortions of metabolite signals. However, this signal can be used for absolute ...quantification and spectral corrections. We investigated the feasibility of water‐unsuppressed MRSI in patients with prostate cancer for water signal–mediated spectral quality improvement and determination of absolute tissue levels of choline.
Methods
Eight prostate cancer patients scheduled for radical prostatectomy underwent multi‐parametric MRI at 3 T, including 3D water‐unsuppressed semi‐LASER MRSI. A postprocessing algorithm was developed to remove the water signal and its artifacts and use the extracted water signal as intravoxel reference for phase and frequency correction of metabolite signals and for absolute metabolite quantification.
Results
Water‐unsuppressed MRSI with dedicated postprocessing produced water signal and artifact‐free MR spectra throughout the prostate. In all patients, the absolute choline tissue concentration was significantly higher in tumorous than in benign tissue areas (mean ± SD: 7.2 ± 1.4 vs 3.8 ± 0.7 mM), facilitating tumor localization by choline mapping. Tumor tissue levels of choline correlated better with the commonly used (choline + spermine + creatine)/citrate ratio (r = 0.78 ± 0.1) than that of citrate (r = 0.21 ± 0.06). The highest maximum choline concentrations occurred in high‐risk cancer foci.
Conclusion
This report presents the first successful water‐unsuppressed MRSI of the whole prostate. The water signal enabled amelioration of spectral quality and absolute metabolite quantification. In this way, choline tissue levels were identified as tumor biomarker. Choline mapping may serve as a tool in prostate cancer localization and risk scoring in multi‐parametric MRI for diagnosis and biopsy procedures.
Until now,
H MRSI of the prostate has been performed with suppression of the large water signal to avoid distortions of metabolite signals. However, this signal can be used for absolute ...quantification and spectral corrections. We investigated the feasibility of water-unsuppressed MRSI in patients with prostate cancer for water signal-mediated spectral quality improvement and determination of absolute tissue levels of choline.
Eight prostate cancer patients scheduled for radical prostatectomy underwent multi-parametric MRI at 3 T, including 3D water-unsuppressed semi-LASER MRSI. A postprocessing algorithm was developed to remove the water signal and its artifacts and use the extracted water signal as intravoxel reference for phase and frequency correction of metabolite signals and for absolute metabolite quantification.
Water-unsuppressed MRSI with dedicated postprocessing produced water signal and artifact-free MR spectra throughout the prostate. In all patients, the absolute choline tissue concentration was significantly higher in tumorous than in benign tissue areas (mean ± SD: 7.2 ± 1.4 vs 3.8 ± 0.7 mM), facilitating tumor localization by choline mapping. Tumor tissue levels of choline correlated better with the commonly used (choline + spermine + creatine)/citrate ratio (r = 0.78 ± 0.1) than that of citrate (r = 0.21 ± 0.06). The highest maximum choline concentrations occurred in high-risk cancer foci.
This report presents the first successful water-unsuppressed MRSI of the whole prostate. The water signal enabled amelioration of spectral quality and absolute metabolite quantification. In this way, choline tissue levels were identified as tumor biomarker. Choline mapping may serve as a tool in prostate cancer localization and risk scoring in multi-parametric MRI for diagnosis and biopsy procedures.
Quality control (QC) is a prerequisite for clinical MR spectroscopic imaging (MRSI) to avoid that bad spectra hamper data interpretation. The aim of this work was to present a simple automatic QC for ...prostate
H MRSI that can handle data obtained with different commonly used pulse sequences, echo times, field strengths, and MR platforms.
A QC method was developed with a ratio (Qratio) where the numerator and the denominator are functions of several signal heights, logically combined for their positive or negative contribution to spectral quality. This Qratio was tested on 4 data sets obtained at 1.5, 3, and 7T, with and without endorectal coil and different localization sequences and echo times. Spectra of 25,248 voxels in 26 prostates were labeled as acceptable or unacceptable by MRS experts as gold standard. A threshold value was determined for Qratio from a subset of voxels, labeled in consensus by 4 experts, for an optimal accuracy to separate spectra.
Applying this Qratio threshold to the remaining test voxels, an automatic separation of good and bad spectra was possible with an accuracy of 0.88, similar to manual separation between the 2 classes. Qratio values were used to generate maps representing spectral quality on a binary or continuous scale.
Automated QC of prostate
H MRSI by Qratio is fast, simple, easily transferable and more practical than supervised feature extraction methods and therefore easy to integrate into different clinical MR systems. Moreover, quality maps can be generated to read the reliability of spectra in each voxel.
Purpose
Quality control (QC) is a prerequisite for clinical MR spectroscopic imaging (MRSI) to avoid that bad spectra hamper data interpretation. The aim of this work was to present a simple ...automatic QC for prostate 1H MRSI that can handle data obtained with different commonly used pulse sequences, echo times, field strengths, and MR platforms.
Methods
A QC method was developed with a ratio (Qratio) where the numerator and the denominator are functions of several signal heights, logically combined for their positive or negative contribution to spectral quality. This Qratio was tested on 4 data sets obtained at 1.5, 3, and 7T, with and without endorectal coil and different localization sequences and echo times. Spectra of 25,248 voxels in 26 prostates were labeled as acceptable or unacceptable by MRS experts as gold standard. A threshold value was determined for Qratio from a subset of voxels, labeled in consensus by 4 experts, for an optimal accuracy to separate spectra.
Results
Applying this Qratio threshold to the remaining test voxels, an automatic separation of good and bad spectra was possible with an accuracy of 0.88, similar to manual separation between the 2 classes. Qratio values were used to generate maps representing spectral quality on a binary or continuous scale.
Conclusion
Automated QC of prostate 1H MRSI by Qratio is fast, simple, easily transferable and more practical than supervised feature extraction methods and therefore easy to integrate into different clinical MR systems. Moreover, quality maps can be generated to read the reliability of spectra in each voxel.
OBJECTIVESInclusion of 3-dimensional H magnetic resonance spectroscopic imaging (3D-H-MRSI) in routine multiparametric MRI of the prostate requires good quality spectra and easy interpretable ...metabolite maps of the whole organ obtained without endorectal coil in clinically feasible acquisition times. We evaluated if a semi-LASER pulse sequence with gradient offset independent adiabaticity refocusing pulses (GOIA-sLASER) for volume selection can meet these requirements.
MATERIALS AND METHODSThirteen patients with suspicion of prostate cancer and 1 patient known to have prostate cancer were examined at 3 T with a multichannel body-receive coil. A 3D-H-MRSI sequence with GOIA-sLASER volume selection (echo time, 88 milliseconds) was added to a routine clinical multiparametric MRI examination of these patients. Repetition times from 630 to 1000 milliseconds and effective voxel sizes of approximately 0.9 and 0.6 cm were tested. Spectral components were quantified by LCModel software for quality assessment and to construct choline and citrate maps.
RESULTSThree-dimensional MRSI of the prostate was successfully performed in all patients in measurement times of 5 to 10 minutes. Analysis of the multiparametric MRI examination or of biopsies did not reveal malignant tissue in the prostate of the 13 patients. In 1404 evaluated voxels acquired from 13 patients, the citrate resonance could be fitted with a high reliability (Cramér-Rao lower bound <30%), 100% for 7 × 7 × 7-mm voxels and 96 ± 7 in 6 × 6 × 6-mm voxels. The percentage of 7 × 7 × 7-mm voxels in which the choline signal was fitted with Cramér-Rao lower bound of less than 30% was approximately 50% at a TR of 630 milliseconds and increased to more than 80% for TRs of 800 milliseconds and above. In the patient with prostate cancer, choline was detectable throughout the prostate in spectra recorded at a TR of 700 milliseconds. The homogeneous B1 field over the prostate of the receive coil enabled the generation of whole organ metabolite maps, revealing choline and citrate variations between areas with normal prostate tissue, seminal vesicles, proliferative benign prostatic hyperplasia, and tumor.
CONCLUSIONSThe good signal-to-noise ratio and low chemical shift artifacts of GOIA-sLASER at an echo time of 88 milliseconds enable acquisition of high-quality 3D-H-MRSI of the prostate without endorectal coil in less than 10 minutes. This facilitates reconstruction of easy interpretable, quantitative metabolite maps for routine clinical applications of prostate MRSI.
To investigate the associations of metabolite levels derived from magnetic resonance spectroscopic imaging (MRSI) and
F-fluciclovine positron emission tomography (PET) with prostate tissue ...characteristics.
In a cohort of 19 high-risk prostate cancer patients that underwent simultaneous PET/MRI, we evaluated the diagnostic performance of MRSI and PET for discrimination of aggressive cancer lesions from healthy tissue and benign lesions. Data analysis comprised calculations of correlations of mean standardized uptake values (SUV
), maximum SUV (SUV
), and the MRSI-derived ratio of (total choline + spermine + creatine) to citrate (CSC/C). Whole-mount histopathology was used as gold standard.
The results showed a moderate significant correlation between both SUVmean and SUVmax with CSC/C ratio.
We demonstrated that the simultaneous acquisition of
F-fluciclovine PET and MRSI with an integrated PET/MRI system is feasible and a combination of these imaging modalities has potential to improve the diagnostic sensitivity and specificity of prostate cancer lesions.
PDF
